TorEx Lung Perfusion System

Lung Transplant Clinical Trial

Official title:

Evaluation of the TorEx Lung Perfusion System in Clinical Lung Transplantation: A Safety Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05656404
• Other study ID #: 22-5156
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 6, 2022
• Est. completion date: May 28, 2024

Study information

• Verified date: January 2024
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lung transplantation is a life-saving and life-prolonging therapy for patients with end-stage lung disease. However, the number of patients listed for lung transplantation exceeds the number of available donor lungs, leading to long wait times, deterioration in health and death of some listed patients. One way to address this issue is to reduce the number of donor lungs that are deemed unusable (declined) for transplantation. Often, donor lungs are declined for transplantation based on questionable function or inability to fully assess the organ in the donor. Due to this reason, up to 80% of potentially suitable lungs may be discarded. As a result, ex vivo lung perfusion (EVLP) was developed.

EVLP is a technique that enables the donor lungs to function in near physiological conditions outside the body, allowing surgeons to evaluate the suitability of the donor lungs for transplantation. Using this technique, centers have reported the recovery of around 70% of donor lungs that would have otherwise been deemed unusable and discarded.

The first generation Toronto EVLP technique started as a clinical trial in 2008 and became a part of the clinical standard of care at Toronto General Hospital in 2011. Since then, many clinical studies have shown that short- and long-term outcomes of recipients who received donor lungs assessed by the Toronto EVLP system were similar to those who received donor lungs deemed suitable to go straight to transplantation.

In partnership with Traferox Technologies Inc., surgeons and research team members developed the second generation TorEx Lung Perfusion System, which addresses engineering design limitations of the original Toronto EVLP system. It optimizes the Toronto EVLP technique by combining all the necessary equipment required to perform the procedure, while placing their controls within a central location. The technique of perfusion and ventilation as well as the perfusate solution remain the same between the two EVLP systems. Prior to this study, the TorEx Lung Perfusion System has not been used in clinical human lung transplantation.

The first purpose of this study is to look at the safety of using the TorEx Lung Perfusion System in 20 consented recipients. The second purpose to compare post-transplant outcomes between recipients who received donor lungs assessed by the TorEx Lung Perfusion System and a historical cohort of recipients who received donor lungs that were assessed by the first generation Toronto EVLP system.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: May 28, 2024
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Recipient Inclusion Criteria

• Actively listed for primary lung transplantation

• Written, informed consent provided

• 18-80 years old

Recipient Exclusion Criteria

• Re-transplantation

• Multi-organ transplantation

• Participation in another interventional trial

Donor Inclusion Criteria

• Age =70 years old

• Ex vivo lung perfusion clinically indicated for donor lungs

Donor Exclusion Criteria

• Age >70 years old

• Donor lungs suitable to go straight to transplantation

EVLP Transplant Suitability

• Pulmonary vein PO2 > 400mmHg

• Stability or improvement of other lung function parameters during EVLP (PVR, Compliance, Airway Pressures)

• Surgeon clinically satisfied with lung evaluation

Related Conditions & MeSH terms

• Ex Vivo Lung Perfusion
• Lung Transplant

Intervention

Device:
• TorEx Lung Perfusion System
When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).

Locations

Country	Name	City	State
Canada	Toronto General Hospital, University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of ISHLT Primary Graft Dysfunction Grade 3		72 hours post-transplant
Secondary	Overall survival		30 days, 1 year post-transplant
Secondary	Time on ventilator		Perioperative
Secondary	ICU and hospital length of stay		Perioperative
Secondary	Occurrence of acute rejection		1 year post-transplant
Secondary	Six minute walk test		1 year post-transplant
Secondary	Forced expiratory volume - one second (FEV1 in L)		1 year post-transplant